drugset / Trial / NCT07689539
Trial of DN022150 Versus Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation
RandomizedParallel-groupOpen-labelTreatment
Summary
This study plans to enroll participants with previously treated advanced pancreatic cancer and harbor centrally confirmed KRAS G12D mutation. Eligible participants will be randomized 1:1 to DN022150 Monotherapy or Investigator's Choice Chemotherapy
Timeline
- Start
- 2026-09
- Primary completion
- 2028-07
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Chemotherapy | Unknown | — | — |
| Subject | DN022150 | Unknown | — | Intravenous |
| Subject | S-1 | Small molecule | — | — |
| Subject | fluorouracil | Small molecule | — | — |
| Subject | nal-IRI | Unknown | — | — |